成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Micafungin

Micafungin Struktur
235114-32-6
CAS-Nr.
235114-32-6
Englisch Name:
Micafungin
Synonyma:
Micfungin;MICAFUNGIN;Micafungin Na;Micafungin-d11;Micafungin (Acid);PubChem ID: 477468;PubChem ID: 3081921;PubChem ID: 11804463;PubChem ID: 78357831;Micafungin USP/EP/BP
CBNumber:
CB71471028
Summenformel:
C56H71N9O23S
Molgewicht:
1270.28
MOL-Datei:
235114-32-6.mol

Micafungin Eigenschaften

Schmelzpunkt:
>198oC (dec.)
Dichte
1.62±0.1 g/cm3(Predicted)
storage temp. 
Hygroscopic, -20°C Freezer, Under inert atmosphere
L?slichkeit
DMSO (Slightly), Methanol (Very Slightly, Heated)
pka
-4.46±0.18(Predicted)
Aggregatzustand
Solid
Farbe
White to Off-White
Stabilit?t:
Hygroscopic

Sicherheit

Micafungin Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Micafungin, the second member of the echinocandin class of antifungal agents was launched in Japan for the parenteral treatment of various fungal infections caused by Aspergillus and Candida spp. such as fungaemia and respiratory and gastrointestinal mycoses. This water-soluble semisynthetic cyclic lipopeptide is synthesized by acylation with (5-(4- pentyloxyphenyl)isoxazol-3-yl)benzoate of the cyclic peptide nucleus (FR-179642).obtained by enzymatic cleavage of the naturally occurring echinocandin FR-901379, derived from the fungus Coleophoma empedri Micafungin acts by inhibiting the synthesis of 1,3-beta-glucan, an essential polysaccharide of the cell wall of many pathogenic fungi. Micafungin has a marked fungicidal effect on almost all species of Candida, including fluconazole-resistant spp. C. albicans, C. glabrata, C. Krusei, C. parapsilosis and C. tropicalis and a fungistatic effect on a range of Aspergillus species including A. flaws, A. fumigates and A. terreus. Like caspofungin, micafungin is inactive against Cryptococcus neoformans, and the emerging pathogen Trichosporon cutaneum and Fusarium solani. Micafungin has proved highly effective in mouse models of Cancfidiasis and Aspergillus infections (including those using an amphotericin B- and itraconazole-resistant isolate of A. fumigatus). In phase I studies, micafungin had linear pharmacokinetics with an elimination half-life ranging from 11.7 to 15.2 h after injection and was well tolerated.

Verwenden

Micafungin is a semi-synthetic cyclic lipopeptide belonging to the echinocandin class that was reported in 1999 from Fujisawa in Japan. Unlike other marketed semi-synthetic derivatives in this class, micafungin is not derived from echinocandin but rather from FR901379 which contains a phenolic sulphate to enhance aqueous solubility, a serious limitation in the class. Micafungin inhibits the synthesis of β-(1,3)-D-glucan, an essential component of the cell wall of susceptible fungi and is extensively referenced in the literature with over 700 citations.

Definition

ChEBI: A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invas ve candidiasis, and of aspergillosis in patients who are intolerant of other therapy.

Antimicrobial activity

It is active against Aspergillus spp., Candida spp. and the cyst form of Pn. jirovecii. Resistance has rarely been reported.

Pharmazeutische Anwendungen

A semisynthetic lipopeptide derived from a fermentation product of Coleophoma empetri. Formulated as the monosodium salt for intravenous infusion.

Pharmakokinetik

Cmax 50 mg 1-h infusion: c. 5 mg/L 1 h post infusion
Plasma half-life: 11–15 h
Volume of distribution: 0.4 L/kg
Plasma protein binding: 99%
Blood concentrations increase in proportion to dosage. Unlike anidulafungin and caspofungin, a loading dose is not required.
Distribution
The drug is widely distributed, the highest concentrations being found in the liver. Levels in the CSF and urine are negligible.
Metabolism and excretion
It is metabolized by the liver and the three inactive metabolites are excreted in the feces (70%). Less than 1% of a dose is eliminated as unchanged drug in the urine. No dosage adjustment is required in patients with severe renal impairment or mild to moderate hepatic impairment. The effect of severe hepatic impairment on micafungin pharmacokinetics has not been studied. Micafungin is not cleared by hemodialysis.

Clinical Use

Candidemia and certain invasive forms of candidosis
Esophageal candidosis
Prophylaxis of Candida infections in hematopoietic stem cell transplant (HSCT) recipients

Nebenwirkungen

Occasional histamine-mediated infusion-related reactions, injection site reactions and transient abnormalities of liver enzymes have been reported. Isolated cases of significant hepatic or renal dysfunction, hepatitis, or liver or renal failure have also been described.

Micafungin Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Micafungin Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 162)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
AFINE CHEMICALS LIMITED
+86-0571-85134551
sales@afinechem.com China 15354 58
Shaanxi Haibo Biotechnology Co., Ltd
+undefined18602966907
qinhe02@xaltbio.com China 997 58
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21634 55
Shanghai Yingrui Biopharma Co., Ltd.
+86-21-33585366 - 03@
sales03@shyrchem.com CHINA 738 60
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795
ivan@atkchemical.com China 32951 60
AB PharmaTech,LLC
323-480-4688
sales@acrospharmatech.com United States 989 55
career henan chemical co
+86-0371-86658258 +8613203830695
sales@coreychem.com China 29884 58
Standardpharm Co. Ltd.
86-714-3992388
overseasales1@yongstandards.com United States 14332 58
Chongqing Chemdad Co., Ltd
+86-023-6139-8061 +86-86-13650506873
sales@chemdad.com China 39894 58
Shanghai Yingrui Biopharma Co.,Ltd
21-33585366
export01@shyrchem.com CHINA 1319 58

235114-32-6()Verwandte Suche:


  • MICAFUNGIN
  • Micafungin (Acid)
  • PneuMocandin A0,1-[(4R,5R)-4,5-dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-
  • Micafungin-d11
  • Micfungin
  • PubChem ID: 11804463
  • PubChem ID: 122130057
  • PubChem ID: 477468
  • PubChem ID: 78357831
  • PubChem ID: 3081921
  • Micafungin Na
  • Micafungin USP/EP/BP
  • Micafungin(free acid)
  • TIANFU-CHEM Micafungin
  • Pneumocandin A0,1-[(4R,5R)-4,
  • 2H11]-Micafungin Sodium salt
  • 5-((1S,2S)-2-((2R,9S,11R,12R,14aS,15S,16S,20S,25aS)-20-((R)-3-Amino-1-hydroxy-3-oxopropyl)-2,11,12,15-tetrahydroxy-6-((R)-1-hydroxyethyl)-16-methyl-5,8,14,19,22,25-hexaoxo-9-(4-(5-(4-(pentyloxy)phenyl)isoxazol-3-yl)benzamido)tetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-23-yl)-1,2-dihydroxyethyl)-2-hydroxyphenyl hydrogen sulfate
  • {5-[(1S,2S)-2-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-3-[(1R)-2-carbamoyl-1-hydroxyethyl]-11,20,21,25-tetrahydroxy-15-[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-(4-{5-[4-(pentyloxy)phenyl]-1,2-oxazol-3-yl}benzamido)-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0?,13]heptacosan-6-yl]-1,2-dihydroxyethyl]-2-hydroxyphenyl}oxidanesulfonic acid
  • 235114-32-6
  • C56H71N9O23S
  • API
  • Inhibitors
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Aromatics
  • Heterocycles
  • Antifungals
  • 235114-32-6
Copyright 2019 ? ChemicalBook. All rights reserved